On February 6, Dr. Jun Bao, MBA’99, had an interesting dialogue on business development in biomedicine with Clifford Stocks who also holds an MBA from the Booth School of Business, in front of an enthusiastic audience gathered at the University of Chicago Center in Beijing.
Clifford J. Stocks is the Founder and Chief Executive Officer of OncoResponse, Inc., a Seattle based biotech company focused on immuno-oncology which was formed through a strategic alliance between Theraclone Sciences and MD Anderson Cancer Center. Recently he was CEO of Theraclone where he oversaw the successful development of several therapeutic antibodies focused on infectious diseases, including monoclonal antibodies, for HIV-cure licensed to Gilead. Mr. Stocks’ career includes 15 years at ICOS corporation, where he served as an Executive Officer and Vice President of Business Development. He was a key architect of the Lilly ICOS joint venture partnership leading to their $2.3 billion merger in 2007. His early career includes academic research on staff in the department of molecular genetics and cell biology at the University of Chicago, where he received his MBA from.
50 people from research institutions, manufacturers, sales companies, consulting firms, universities, law firms, and financial and insurance companies attended the event. The dialogue helped the audience to further understand the strategies and skills needed in business development of the biomedicine industry.
Jun Bao, MBA’99, PhD, is Senior Vice President and Chief Business Officer, Acting Chief Financial Officer, Member of Board of Directors of the Beijing Shenogen Biomedical Co., Ltd.
The event was co-organized by the Tongxieyi Club, University of Chicago Beijing Alumni Club and the BayHelix Group.